Invanz (ertapenem)
- Region
- 🇪🇺 EU
- Active substance
- ertapenem
- Company
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- Therapeutic area
- Community-Acquired Infections; Streptococcal Infections; Staphylococcal Infections; Gram-Negative Bacterial Infections; Surgical Wound Infection; Pneumonia, Bacterial
- EU approval
- Thu 18 Apr 2002
- Application
- EMEA/H/C/000389
- ATC
- J01DH03
- Official record
- www.ema.europa.eu
Indication
Treatment Treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required: intra-abdominal infections; community-acquired pneumonia; acute gynaecological infections; diabetic foot infections of the skin and soft tissue. Prevention Invanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ertapenem SUN Authorised · SUN Pharmaceutical Industries (Europe) B.V.
- 🇪🇺 Ertapenem Hospira Application withdrawn · Hospira UK Limited
Follow Invanz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.